Antidiabetic activity of methanolic root extract of mukia Maderaspatana in alloxan induced diabetic rats

International Journal of PharmTech Research

Volumn 3, Issue 1, 2011, Pages 214-220

  Wani, V K ^a   Dubey, R D ^b   Verma, S ^b   Sengottuvelu, S ^a   Sivakumar, T ^a  

^a NANDHA COLLEGE OF PHARMACY   (India)

^b RITEE   (India)

Author keywords

Alloxan; Antidiabetic activiy; Mukia Maderaspatana

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALLOXAN; ANTIDIABETIC AGENT; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLIBENCLAMIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MUKIA MADERASPATANA EXTRACT; PHOSPHOLIPID; PLANT EXTRACT; PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; LIPID BLOOD LEVEL; MALE; MEDICINAL PLANT; MUKIA MADERASPATANA; NONHUMAN; PHOSPHOLIPID BLOOD LEVEL; PROTEIN BLOOD LEVEL; RAT; SINGLE DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79951560934     PISSN: None     EISSN: 09744304     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Amos AF, Mc carty DJ, Zimmet P. The rising global burden of diabetes and its complication. Diabetic medicine. 1997; 14:51-85.
2. Bajaj JS, Madan R. Diabetes in tropics and developing countries. IDF bulletin. 1995; 38(2): 5-6.
3. David MN, The pathophysiology of diabetic complication. How much dose the glucose hypotheses explain? Annals of Internal Medicine. 1996; 174 (1pt):286-289.
4. Holman RR, Turner RC, Oral agent and insulin in the treatment of NIDDM In, Pickup, J., Williams, G., (Eds), and Text book of Diabetes. Black well, oxford. 1991; 174:467-469.
5. Bodansky H, The natural history of diabetes. Practical diabetes. 1989; vol. 6: No.1:p. 29.
6. Printz RL, Magnuson MA, Granner DK, Mammalian glucokinase. Annual Review of Nutrition. 1993; 13:463-496.
7. Sethi PD, Identification of drugs in formulations by TLC. 2nd ed. CBS Publishers & Distributors; New Delhi: 2004.P. 241.
8. Horborne JB, Phytochemical methods. 3rd ed. Spriger private limited; New Delhi: 1998.p. 60, 52.
9. Nandhakumar J, Sethumathi PP, Anti-diabetic activity of methanol leaf extract of Coctus pictus D. DON in alloxan induced diabetic rats. Journal of Health Science. 2007; 53 (6):665-663.
10. Scoppala A, Montecchi FR, Mezinger G, Lala A, Atherosclerosis. 2001;156:357-361.
11. Kraus-Friendmann N, Hornonal regulation of hepatic gluconeogenesis. Physiology Review. 1984; 64:p. 1706.
12. Austin MA, Hokanson JE, Epidermiology of triglyceride, small dense low density lipoprotein and lipoprotein (a) as risk factor for coronary heart disease. Medicine Clinics North America. 2004; 78:99-115.
13. Brown MS, Goldstein JL, Lipoprotein receptor in the liver. Control signals for plasma cholesterol traffic. The journals of Clinical Investigation. 1983; 72:743-7.
14. Luc G, Fruchart JC, American Journals of Clinical Nutrition. 1991; 53:2065-2095.
15. Felig P, Marliss E, Ohman J, Cahil Jr JF, Plama aminoacinos level in diabetic ketoacidosis. Diabetes. 1970; 19:p. 727.
16. Sumana G, Suryawashi SA, Effect of vinka rosea extracts in treatment of alloxan diabetes in male albino rats. Indian Journal of Express Biology. 2001; 39:748-759.